Revenues from Pall’s biopharmaceuticals division grew in fiscal 2009, excluding foreign currency changes, with the company benefiting from the “thriving market” for vaccines and expanding adoption of single-use systems.
Patheon has posted “disappointing” Q3 results, with manufacturing difficulties in Puerto Rico, a slowdown in demand for development services and reduced client demand for some products impacting on revenues.
Cambrex has posted a positive set of Q2 results, recording an operating income of $9m (€6.3m), but warned that the second half of the year is likely to be down on the corresponding six months of last year.
Cincinatti, US-based clinical research organization Kendle has cut back its revenue expectations for 2008, primarily as a result of the strengthening of the US dollar, in common with some of its peers in the CRO sector.
Contract development and manufacturing company Patheon received an unsolicited takeover bid from private equity firm JLL Partners ahead of reporting a return to profit in its fiscal fourth quarter results.
Pall seems to have shaken off the financial turmoil of recent
months in the second quarter of 2008, with a 15 per cent hike in
sales to $626m helped by favourable dollar exchange rates and a
strong performance by its biopharmaceuticals...
The Hovione Group revealed its yearly figures for 2005, which
revealed that sales grew by 8 per cent. The company's performance
is in contrast to the pharma fine chemicals sector, which between
2002 and 2004 had an average 14...
Yesterday, German chemicals group Degussa said that it had got off
to a good start financially in 2004. Today, the company provided a
more detailed breakdown of the first-quarter results which shows
the fine chemicals division still...